177Lu PSMA RLT / 3B Pharma - LARVOL DELTA

Prognostic value of interim post-treatment SPECT/CT following lutetium-177 (177Lu)-PSMA therapy in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. (PubMed, Front Med (Lausanne)) - "Following PRISMA guidelines and PICO framework, PubMed/MEDLINE, Scopus, and Google Scholar were searched up to December 2025 for studies on mCRPC patients receiving 177Lu-PSMA RLT with early post-treatment SPECT/CT...Interim 177Lu-PSMA SPECT/CT offers prognostic insights, with new lesions and TTV increases signaling poor outcomes. Standardization and prospective validation are needed to integrate it into clinical practice."

Journal • Retrospective data • Review • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Outcome and Safety of Radioligand Therapy With [161Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [177Lu]Lu-PSMA-617. (PubMed, Clin Nucl Med) - P=N/A | "[161Tb]Tb-PSMA-617 RLT emerges as a promising treatment option, demonstrating encouraging response rates, preliminary clinical outcomes, and a favorable safety profile as second-line RLT in progressing patients who previously benefited from [177Lu]Lu-PSMA-617 RLT."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer. (PubMed, BJU Int) - "International guidelines largely converge on patient selection, dosing, and multidisciplinary implementation of PSMA-RLT. Ongoing trials including PSMAfore, PSMAddition, UpFrontPSMA, ENZA-p, and LuTectomy are expected to further define its role in earlier and combination treatment settings."

Journal • Review • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urology

Renal and Hematologic Toxicity Profile of [177] Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT): A Retrospective Cohort Study. (PubMed, Rev Esp Med Nucl Imagen Mol (Engl Ed)) - "No clinically significant nephrotoxicity was observed with 177Lu-PSMA-RLT. Hematologic toxicity is significant but manageable, and severe side effects are rare and within predictable limits."

Journal • Retrospective data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hematological Disorders • Oncology • Prostate Cancer • Solid Tumor

Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT (clinicaltrials.gov) - P1/2 | N=29 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=70 ➔ 29

Enrollment change • Enrollment closed • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor